Sigilon Therapeutics, Inc.
(NASDAQ GS: SGTX)
Rigrodsky Law, P.A. is investigating Sigilon Therapeutics, Inc. (“Sigilon”) regarding possible breaches of fiduciary duties and other violations of law related to Sigilon’s agreement to be acquired by Eli Lilly and Company. Under the terms of the agreement, Sigilon shareholders will receive $14.92 per share in cash.